Clinical Trial Update: A Study of Clenbuterol (CST-103) Co-administered With Nadolol (CST-107) in Subjects With Neurodegenerative Disorders [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update reporting completed status and posted results for clenbuterol (CST-103) co-administered with nadolol (CST-107) in people with neur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Impairment
• Lewy Body Dementia
• Parkinson Disease Dementia
• Parkinson Disease with Rem Sleep Behavior Disorder

Drugs mentioned

• Clenbuterol (CST-103) (clenbuterol)
• Nadolol (CST-107) (nadolol)

Snippet

Sponsor: CuraSen Therapeutics, Inc. | Conditions: Mild Cognitive Impairment, Lewy Body Dementia, Parkinson's Disease Rapid Eye Movement Sleep Behavior Disorder, Parkinson's Disease Dementia | Phase 2 | Status: COMPLETED | Results posted: 2024-12-02